JP2012518398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518398A5 JP2012518398A5 JP2011550601A JP2011550601A JP2012518398A5 JP 2012518398 A5 JP2012518398 A5 JP 2012518398A5 JP 2011550601 A JP2011550601 A JP 2011550601A JP 2011550601 A JP2011550601 A JP 2011550601A JP 2012518398 A5 JP2012518398 A5 JP 2012518398A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding
- binding construct
- domain
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 2
- 210000003423 ankle Anatomy 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 210000003127 knee Anatomy 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 claims 1
- 102000003930 C-Type Lectins Human genes 0.000 claims 1
- 108090000342 C-Type Lectins Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010059013 Chaperonin 10 Proteins 0.000 claims 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 102000000470 PDZ domains Human genes 0.000 claims 1
- 108050008994 PDZ domains Proteins 0.000 claims 1
- 108010079855 Peptide Aptamers Proteins 0.000 claims 1
- 208000018286 Shoulder injury Diseases 0.000 claims 1
- 208000020339 Spinal injury Diseases 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000013069 gamma-Crystallins Human genes 0.000 claims 1
- 108010079934 gamma-Crystallins Proteins 0.000 claims 1
- 210000001624 hip Anatomy 0.000 claims 1
- 210000004394 hip joint Anatomy 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15488009P | 2009-02-24 | 2009-02-24 | |
| US61/154,880 | 2009-02-24 | ||
| PCT/EP2010/052283 WO2010097385A1 (en) | 2009-02-24 | 2010-02-23 | Antigen-binding constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012518398A JP2012518398A (ja) | 2012-08-16 |
| JP2012518398A5 true JP2012518398A5 (OSRAM) | 2013-04-11 |
Family
ID=42174088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550601A Pending JP2012518398A (ja) | 2009-02-24 | 2010-02-23 | 抗原結合性構築物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110305692A1 (OSRAM) |
| EP (1) | EP2401298A1 (OSRAM) |
| JP (1) | JP2012518398A (OSRAM) |
| CA (1) | CA2753287A1 (OSRAM) |
| WO (1) | WO2010097385A1 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| JP2012527878A (ja) * | 2009-05-28 | 2012-11-12 | グラクソ グループ リミテッド | 抗原結合タンパク質 |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| ES2948572T3 (es) | 2009-07-08 | 2023-09-14 | Kymab Ltd | Modelos de roedores y moléculas terapéuticas |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| CA2815267C (en) * | 2010-10-27 | 2019-06-25 | Spiber Technologies Ab | Spider silk fusion protein structures for binding to an organic target |
| CN103619876A (zh) * | 2011-03-10 | 2014-03-05 | Hco抗体股份有限公司 | 双特异性三链抗体样分子 |
| KR102072250B1 (ko) * | 2011-05-27 | 2020-03-02 | 아블린쓰 엔.브이. | Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| PE20141659A1 (es) * | 2011-07-27 | 2014-11-21 | Glaxo Group Ltd | Dominios variables singulares anti-vgf fusionados con dominios de fc |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JP6412866B2 (ja) | 2012-05-02 | 2018-10-24 | スパイバー テクノロジーズ アーベーＳｐｉｂｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ａｂ | 有機ターゲットに結合するための反復断片を持たないクモ糸融合タンパク質の構造 |
| WO2013164404A1 (en) | 2012-05-02 | 2013-11-07 | Spiber Technologies Ab | Spider silk fusion protein structures incorporating immunoglobulin fragments as affinity ligands |
| CA2891510C (en) | 2012-11-16 | 2022-10-18 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
| HK1220466A1 (zh) | 2013-03-14 | 2017-05-05 | Regeneron Pharmaceuticals, Inc. | 爱帕琳融合蛋白和其用途 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| MX377716B (es) | 2013-11-20 | 2025-03-11 | Regeneron Pharma | Moduladores de aplnr y usos de estos. |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| JP2017518082A (ja) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス， インコーポレイテッド | ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| ES2886599T3 (es) | 2015-06-17 | 2021-12-20 | Poseida Therapeutics Inc | Composiciones y métodos para dirigir proteínas a loci específicos en el genoma |
| WO2024015748A1 (en) * | 2022-07-11 | 2024-01-18 | Amgen Inc. | Treatment of erosive hand osteoarthritis |
| FR3147292A1 (fr) * | 2023-03-31 | 2024-10-04 | Affyxell Therapeutics Co., Ltd. | Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations |
| WO2024200987A1 (en) * | 2023-03-31 | 2024-10-03 | Avacta Life Sciences Limited | Tnfr2 binding polypeptides and methods of use |
| FR3147278A1 (fr) * | 2023-03-31 | 2024-10-04 | Avacta Life Sciences Limited | Polypeptides de liaison au tnfr2 et procedes d'utilisation |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| DK1019496T3 (da) | 1997-07-07 | 2005-01-10 | Medical Res Council | In vitro-sorteringsmetode |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| PT1078051E (pt) | 1998-05-13 | 2008-03-17 | Domantis Ltd | Sistema de apresentação em fagos para a selecção de proteínas correctamente organizadas |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| GB9900298D0 (en) | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
| CA2399809A1 (en) | 2000-02-03 | 2001-08-09 | Domantis Limited | Combinatorial protein domains |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
| ES2337986T3 (es) | 2001-08-10 | 2010-05-03 | Aberdeen University | Dominios de union de antigenos de peces. |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| JP4871126B2 (ja) | 2003-07-04 | 2012-02-08 | アフィボディ・アーベー | Ｈｅｒ２に対する結合親和性を有するポリペプチド |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| EP2520588A1 (en) * | 2005-08-19 | 2012-11-07 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| JP2009526857A (ja) | 2006-02-15 | 2009-07-23 | イムクローン・リミテッド・ライアビリティ・カンパニー | 機能性抗体 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| MX2009012650A (es) * | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| CA2688434A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| NZ589434A (en) * | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
-
2010
- 2010-02-23 JP JP2011550601A patent/JP2012518398A/ja active Pending
- 2010-02-23 US US13/202,996 patent/US20110305692A1/en not_active Abandoned
- 2010-02-23 EP EP10711861A patent/EP2401298A1/en not_active Withdrawn
- 2010-02-23 CA CA2753287A patent/CA2753287A1/en not_active Abandoned
- 2010-02-23 WO PCT/EP2010/052283 patent/WO2010097385A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518398A5 (OSRAM) | ||
| JP2016524592A5 (OSRAM) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| ES2918626T3 (es) | Receptor antigénico quimérico. | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2017163973A5 (OSRAM) | ||
| JP2019507589A5 (OSRAM) | ||
| JP2017529067A5 (OSRAM) | ||
| JP2012501670A5 (OSRAM) | ||
| WO2010115995A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders | |
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| HRP20180937T1 (hr) | Poboljšavanje transporta terapijskih molekula kroz krvno-moždanu barijeru | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2016501839A5 (OSRAM) | ||
| JP2017029157A5 (OSRAM) | ||
| JP2016511254A5 (OSRAM) | ||
| JP2017522903A5 (OSRAM) | ||
| AR080840A1 (es) | Proteinas que se unen al tnf-alfa (factor de necrosis tumoral alfa humano) | |
| RU2016101711A (ru) | Высокостабильный т-клеточный рецептор и способ его получения и применения | |
| JP2020501550A5 (OSRAM) | ||
| HRP20200679T1 (hr) | Molekule koje vežu antigen i sadrže trimer tnf ligand obitelji | |
| JP2012518399A5 (OSRAM) | ||
| JP2018525032A5 (OSRAM) |